- Details
- Zach Klaassen and Kevin Gallagher discuss the RESECT study. RESECT, a global research initiative across five continents and over 200 hospitals, aims to improve the quality of Transurethral Resection of Bladder Tumor (TURBT) surgery and reduce early recurrence rates. Funded in 2020 and launched in late 2020-early 2021, the study utilizes social media marketing and is run on a low budget. It include...
|
- Details
- Ravi Madan discusses the importance of patient-reported outcomes in prostate cancer research. He highlights a presentation centered around the CHAARTED study, which indicated that the three-month quality of life assessment was essential to understanding survival benefits of treatments for prostate cancer patients. In other studies, Dr. Madan notes the limitations of current quality of life metrics...
|
- Details
- In this discussion, Chung-Han Lee delves into his significant contributions to kidney cancer research. Dr. Lee's studies, particularly the KEYNOTE-B61 clinical trial involving non-clear cell renal cell carcinoma patients, are celebrated for their potential to revolutionize treatment practices. This specific trial evaluated the combination of lenvatinib and pembrolizumab and demonstrated a 49% resp...
|
- Details
- Shilpa Gupta shares significant insights on the EV-103 study focused on the four-year outcomes of enfortumab vedotin (EV) and pembrolizumab as a frontline treatment for locally advanced or metastatic urothelial cancer patients who are cisplatin ineligible. Dr. Gupta discusses the 73% response rates, median overall survival exceeding two years, and over 41% of patients remaining progression-free af...
|
- Details
- David VanderWeele elucidates findings from the TALAPRO-2 study, emphasizing the substantial hazard ratio benefits observed in metastatic CRPC patients with HRR mutations, especially those with BRCA1 and 2 mutations, treated with enzalutamide combined with talazoparib. However, he raises questions regarding the true representation of the trial's population and a lack of subsequent PARP inhibitor tr...
|
- Details
- Alicia Morgans converses with Ravi Madan about an ongoing trial involving patients with biochemical recurrence of prostate cancer. The unique trial utilizes Prostate-Specific Membrane Antigen (PSMA) PET imaging to routinely monitor patients and to develop an understanding of the natural history of the disease in the context of recurrent prostate cancer. The goal is to prospectively monitor these p...
|
- Details
- Oliver Sartor discusses the rapidly evolving landscape of radiopharmaceuticals for prostate cancer with Alicia Morgans. Dr. Sartor highlights significant advances, such as the VISION trial, which targets late-stage patients and the PSMAfore trial focusing on pre-chemo patients. He emphasizes the importance of several ongoing trials that could change practice, including one using PSMA lutetium to t...
|
- Details
- Hiten Patel talks about the significant role of the Veterans Health Administration in prostate cancer treatment and research. Dr. Patel outlines the formation of prostate cancer centers of excellence within the VA, intended to coordinate efforts to improve oncology care and survival rates for veterans. The Precision Oncology Program for the Cancer of the Prostate (POPCaP), created in partnership w...
|
- Details
- Veda Giri discusses the promising results of the TARGET study in an interview with Alicia Morgans. The study examined an innovative web-based approach to expand genetic testing access for prostate cancer patients. The study addressed the lack of sustainable patient-genetic counselor interaction by implementing a patient-driven web tool, which was proven to be non-inferior to traditional genetic co...
|
- Details
- Zach Klaassen interviews Lucia Nappi about her research on the role of microRNAs in early-stage testicular cancer. MicroRNAs are small RNA fragments crucial for the regulation of oncogenes and tumor suppressors, with certain microRNAs notably overexpressed in testicular cancer. Dr. Nappi's team analyzed the microRNA-371 in plasma samples from stage I testicular cancer patients, finding that patien...
|
